JP2022541667A5 - - Google Patents
Info
- Publication number
- JP2022541667A5 JP2022541667A5 JP2022505447A JP2022505447A JP2022541667A5 JP 2022541667 A5 JP2022541667 A5 JP 2022541667A5 JP 2022505447 A JP2022505447 A JP 2022505447A JP 2022505447 A JP2022505447 A JP 2022505447A JP 2022541667 A5 JP2022541667 A5 JP 2022541667A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- tautomer
- solvate
- pharmaceutical composition
- adenosine derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962879414P | 2019-07-27 | 2019-07-27 | |
| US62/879,414 | 2019-07-27 | ||
| PCT/US2020/043713 WO2021021717A1 (en) | 2019-07-27 | 2020-07-27 | Adenosine derivative and pharmaceutical composition comprising the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022541667A JP2022541667A (ja) | 2022-09-26 |
| JP2022541667A5 true JP2022541667A5 (https=) | 2023-08-07 |
| JP7700096B2 JP7700096B2 (ja) | 2025-06-30 |
Family
ID=74229552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022505447A Active JP7700096B2 (ja) | 2019-07-27 | 2020-07-27 | アデノシン誘導体及びそれを含む薬学的組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12370208B2 (https=) |
| EP (1) | EP4003369A4 (https=) |
| JP (1) | JP7700096B2 (https=) |
| KR (1) | KR20220068987A (https=) |
| CN (1) | CN114502175B (https=) |
| AU (1) | AU2020320876B2 (https=) |
| BR (1) | BR112022000965A2 (https=) |
| CA (1) | CA3146679A1 (https=) |
| IL (1) | IL289925B2 (https=) |
| MX (1) | MX2022000563A (https=) |
| TW (1) | TWI862645B (https=) |
| WO (1) | WO2021021717A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3445368B1 (en) | 2016-04-21 | 2024-07-17 | Astrocyte Pharmaceuticals, Inc. | Compounds and methods for treating neurological and cardiovascular conditions |
| WO2019014247A1 (en) | 2017-07-11 | 2019-01-17 | Gilead Sciences, Inc. | COMPOSITIONS COMPRISING POLYMERASE RNA INHIBITOR AND CYCLODEXTRIN FOR THE TREATMENT OF VIRAL INFECTIONS |
| CA3146679A1 (en) | 2019-07-27 | 2021-02-04 | Brii Biosciences, Inc. | Adenosine derivative and pharmaceutical composition comprising the same |
| KR20220066303A (ko) | 2019-09-11 | 2022-05-24 | 더 스크립스 리서치 인스티튜트 | 항바이러스 전구약물 및 이의 약제학적 조성물 |
| JP2023512656A (ja) | 2020-01-27 | 2023-03-28 | ギリアード サイエンシーズ， インコーポレイテッド | ＳＡＲＳ ＣｏＶ－２感染を治療するための方法 |
| KR20220153619A (ko) | 2020-03-12 | 2022-11-18 | 길리애드 사이언시즈, 인코포레이티드 | 1'-시아노 뉴클레오사이드의 제조 방법 |
| WO2021188959A1 (en) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| CA3172483A1 (en) | 2020-04-06 | 2021-10-14 | Scott Ellis | Inhalation formulations of 1'-cyano substituted carbanucleoside analogs |
| TW202203941A (zh) | 2020-05-29 | 2022-02-01 | 美商基利科學股份有限公司 | 瑞德西韋之治療方法 |
| PE20230618A1 (es) | 2020-06-24 | 2023-04-14 | Gilead Sciences Inc | Analogos de nucleosido de 1'-ciano y usos de los mismos |
| IL300453A (en) | 2020-08-27 | 2023-04-01 | Gilead Sciences Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS |
| EP4281083A4 (en) | 2021-01-25 | 2025-01-01 | Brii Biosciences, Inc. | COMBINATION THERAPY FOR HIV WITH ADENOSINE DERIVATIVE AND CAPSID INHIBITORS |
| EP4281081A4 (en) | 2021-01-25 | 2025-05-14 | Brii Biosciences, Inc. | ADENOSINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREOF |
| IL307967A (en) * | 2021-04-28 | 2023-12-01 | Astrocyte Pharmaceuticals Inc | Purine nucleosides, their intermediates and methods for their preparation |
| KR20240154647A (ko) | 2022-03-02 | 2024-10-25 | 길리애드 사이언시즈, 인코포레이티드 | 바이러스성 감염 치료를 위한 화합물 및 방법 |
| WO2023196832A2 (en) * | 2022-04-06 | 2023-10-12 | Brii Biosciences, Inc. | Pharmaceutical composition and method for treatment of human immunodeficiency virus infections |
| US12357577B1 (en) | 2024-02-02 | 2025-07-15 | Gilead Sciences, Inc. | Pharmaceutical formulations and uses thereof |
| CR20250310A (es) * | 2023-01-30 | 2025-08-25 | Merck Sharp & Dohme Llc | Profármacos de inhibidores de la transcriptasa inversa de nucleósidos sustituidos en 4' |
| CN121419986A (zh) * | 2023-06-27 | 2026-01-27 | 吉利德科学公司 | 用于制备抗病毒前药的方法和中间体 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5880154A (en) | 1994-02-01 | 1999-03-09 | The Board Of Regents Of The University Of Nebraska | Polymeric adamantane analogues |
| JP2007504232A (ja) * | 2003-09-05 | 2007-03-01 | アナディス ファーマシューティカルズ インク | Ｃ型肝炎ウイルス感染治療用のｔｌｒ７リガンド及びそのプロドラッグの投与 |
| CA2502109C (en) | 2004-03-24 | 2010-02-23 | Yamasa Corporation | 4'-c-substituted-2-haloadenosine derivative |
| WO2007022073A2 (en) * | 2005-08-12 | 2007-02-22 | Merck & Co., Inc. | Novel 2'-c-methyl and 4'-c-methyl nucleoside derivatives |
| WO2008011406A2 (en) | 2006-07-18 | 2008-01-24 | Anadys Pharmaceuticals, Inc. | Carbonate and carbamate prodrugs of thiazolo [4,5-d] pyrimidines |
| WO2011058582A1 (en) | 2009-11-16 | 2011-05-19 | Orchid Research Laboratories Ltd. | Histone deacetylase inhibitors for the treatment of fungal infections |
| US20160199396A1 (en) | 2013-08-29 | 2016-07-14 | Teva Pharmaceutical Industries Ltd. | Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir |
| WO2015143712A1 (en) * | 2014-03-28 | 2015-10-01 | Merck Sharp & Dohme Corp. | 4'-substituted nucleoside reverse transcriptase inhibitors |
| US9951141B2 (en) | 2014-06-02 | 2018-04-24 | Regeneron Pharmaceuticals, Inc. | Antibody-drug conjugates, their preparation and their therapeutic use |
| MX391226B (es) | 2015-09-23 | 2025-03-21 | Merck Sharp & Dohme Llc | Inhibidores de transcriptasa inversa de nucleosido 4'-substituido y preparaciones de los mismos. |
| JOP20170038B1 (ar) | 2016-02-12 | 2021-08-17 | Merck Sharp & Dohme | مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه |
| US20180030080A1 (en) | 2016-07-28 | 2018-02-01 | Alexandre Vasilievich Ivachtchenko | Phosphoramidate nucleoside prodrug for treating viral diseases and cancer, processes for their preparation and their use |
| US10266558B2 (en) | 2016-10-07 | 2019-04-23 | Alexandre Vasilievich Ivachtchenko | Macroheterocyclic nucleoside derivatives and their analogues, production and use thereof |
| US11123355B2 (en) | 2016-12-22 | 2021-09-21 | Idenix Pharmaceuticals Llc | Antiviral benzyl-amine phosphodiamide compounds |
| RU2659388C1 (ru) | 2017-02-28 | 2018-07-02 | Васильевич Иващенко Александр | Нуклеотиды, включающие N-[(S)-1-циклобутоксикарбонил]фосфорамидатный фрагмент, их аналоги и их применение |
| DK3590924T3 (da) | 2017-02-28 | 2022-01-03 | Kangpu Biopharmaceuticals Inc | Hidtil ukendt isoindolinderivat og farmaceutisk sammensætning og anvendelse deraf |
| US20190185508A1 (en) | 2017-12-15 | 2019-06-20 | Merck Sharp & Dohme Corp. | Deuterated nucleoside reverse transcriptase inhibitors |
| US10676252B2 (en) * | 2017-12-21 | 2020-06-09 | Helen Of Troy Limited | Container with sealable lid |
| DE102018200487A1 (de) * | 2018-01-12 | 2019-07-18 | Knorr-Bremse Systeme für Schienenfahrzeuge GmbH | Vorrichtung und Verfahren zur Realisierung kontrollierter Reaktionen bei einer Systemstörung |
| CN109053803A (zh) * | 2018-07-04 | 2018-12-21 | 米文君 | 一类新的化合物及其用途 |
| AU2019317810A1 (en) * | 2018-08-09 | 2021-02-25 | Glaxosmithkline Intellectual Property (No.2) Limited | Compounds useful in HIV therapy |
| JP2021536444A (ja) * | 2018-08-30 | 2021-12-27 | グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited | Ｈｉｖ療法に有用な化合物 |
| CN113811360A (zh) * | 2019-03-06 | 2021-12-17 | 葛兰素史密斯克莱知识产权（第2 号）有限公司 | 用于hiv治疗的化合物 |
| CA3146679A1 (en) | 2019-07-27 | 2021-02-04 | Brii Biosciences, Inc. | Adenosine derivative and pharmaceutical composition comprising the same |
| WO2021038509A1 (en) * | 2019-08-28 | 2021-03-04 | Glaxosmithkline Intellectual Property (No.2) Limited | 4'-ethynyl-2'-deoxyadenosine derivatives and their use in hiv therapy |
| KR20220066303A (ko) * | 2019-09-11 | 2022-05-24 | 더 스크립스 리서치 인스티튜트 | 항바이러스 전구약물 및 이의 약제학적 조성물 |
| EP4171526A4 (en) | 2020-06-27 | 2024-11-27 | Laurus Labs Limited | ORAL FILM FROM HIV MEDICATIONS |
| EP4281081A4 (en) | 2021-01-25 | 2025-05-14 | Brii Biosciences, Inc. | ADENOSINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREOF |
| EP4281083A4 (en) | 2021-01-25 | 2025-01-01 | Brii Biosciences, Inc. | COMBINATION THERAPY FOR HIV WITH ADENOSINE DERIVATIVE AND CAPSID INHIBITORS |
| WO2023196832A2 (en) | 2022-04-06 | 2023-10-12 | Brii Biosciences, Inc. | Pharmaceutical composition and method for treatment of human immunodeficiency virus infections |
-
2020
- 2020-07-27 CA CA3146679A patent/CA3146679A1/en active Pending
- 2020-07-27 CN CN202080066036.3A patent/CN114502175B/zh active Active
- 2020-07-27 TW TW109125342A patent/TWI862645B/zh active
- 2020-07-27 IL IL289925A patent/IL289925B2/en unknown
- 2020-07-27 AU AU2020320876A patent/AU2020320876B2/en active Active
- 2020-07-27 MX MX2022000563A patent/MX2022000563A/es unknown
- 2020-07-27 JP JP2022505447A patent/JP7700096B2/ja active Active
- 2020-07-27 WO PCT/US2020/043713 patent/WO2021021717A1/en not_active Ceased
- 2020-07-27 KR KR1020227006549A patent/KR20220068987A/ko active Pending
- 2020-07-27 US US17/630,403 patent/US12370208B2/en active Active
- 2020-07-27 EP EP20848596.1A patent/EP4003369A4/en active Pending
- 2020-07-27 BR BR112022000965A patent/BR112022000965A2/pt unknown
-
2023
- 2023-02-28 US US18/176,204 patent/US20230226093A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022541667A5 (https=) | ||
| JP2024503723A5 (https=) | ||
| KR100509130B1 (ko) | 친지성 화합물의 자가유화 제제 | |
| JP2016509047A5 (https=) | ||
| RU2662819C2 (ru) | Твердая дисперсия с улучшенной растворимостью, содержащая производное тетразола в качестве активного ингредиента | |
| CA2805206A1 (fr) | Traitement d'une pathologie liee a un effet excessif du tnf par un compose de benzene sulfonamide | |
| JPS5995269A (ja) | 抗てんかん性医薬品 | |
| UA120508C2 (uk) | Комплекси сиролімусу і його похідних, спосіб їх отримання і фармацевтичні композиції, що містять зазначені комплекси | |
| CN113747896A (zh) | 来那度胺和其他免疫调节剂的连续递送 | |
| KR101767296B1 (ko) | 활성제로서 페닐아미노피리미딘 유도체를 포함하는 제제 | |
| CN103012438B (zh) | 烷氧基取代的噻唑并[3,2-b]-1,2,4-三嗪衍生物及其应用 | |
| RU2022104985A (ru) | Аденозиновое производное и фармацевтическая композиция, содержащая его | |
| JP5613396B2 (ja) | 腸管吸収性を改善する医薬組成物 | |
| JP2020511437A5 (https=) | ||
| JP5936609B2 (ja) | キナーゼインヒビターの経口製剤 | |
| JP2013529686A5 (https=) | ||
| CN105163732A (zh) | 用于治疗眼科疾病和病症的方法 | |
| WO2014015153A2 (en) | Compositions and methods for treating ewing's sarcoma and other disorders related to ews-fli1 | |
| WO2005051368A2 (en) | Phosphodiesterase v inhibitor formulations | |
| JPH10503178A (ja) | Ｈｉｖ感染のための組合わせ療法 | |
| KR101118199B1 (ko) | 타크롤리무스를 가용화하기 위한 고분자 미셀 조성물 | |
| EA010293B1 (ru) | Частицеобразующие композиции, содержащие конденсированные пирролокарбазолы | |
| JP2008208122A (ja) | 肥満の予防及び／又は治療薬 | |
| JP4598674B2 (ja) | 統合失調症治療剤 | |
| KR20260057626A (ko) | 프탈라지논 화합물 및 이의 제조 방법, 약학 조성물 및 용도 |